DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Jenburkt Pharmaceuticals Ltd (JENBURPH) share price today?

Jenburkt Pharmaceuticals Ltd (JENBURPH) is trading at ₹1,090.95 on the BSE, up 0.28% on the day. Source: DocStoX.

What is the PE ratio of Jenburkt Pharmaceuticals Ltd?

Jenburkt Pharmaceuticals Ltd has a price-to-earnings (PE) ratio of 15.0 in the Healthcare sector.

What is the market capitalisation of Jenburkt Pharmaceuticals Ltd?

Jenburkt Pharmaceuticals Ltd has a market capitalisation of approximately ₹485 crore.

Jenburkt Pharmaceuticals Ltd

JENBURPH·BSE·Healthcare

₹1,090.95▲ +3.00 (+0.28%)

Healthcare · Pharmaceuticals & Biotechnology

Debt-free and consistently profitable

Day₹1087.85

₹1104.90

52W₹944

₹136535%

Open

₹1087.90

High

₹1104.90

Low

₹1087.85

Prev Close

₹1087.95

Volume

352

VWAP

₹1095.54

Snapshot

Key fundamentals

Market Cap

₹485 Cr

P/E Ratio

15.02Fair

P/B Ratio

2.44

EPS

₹72.64

Book Value

₹446.48

ROE

18.66%Strong

ROCE

27.00%Efficient

Dividend Yield

1.65%

Debt / Equity

0.01Low

Face Value

₹10.00

52W High

₹1364.90

52W Low

₹944.00

Sector

Healthcare

Industry

Pharmaceuticals & Biotechnology

Avoid

Narrow moatMedium uncertainty

Fair value estimate

₹640

▼ 41.3%downside

Trading at ₹1,091 — 41% above our estimate

BearFair valueBull

₹544₹640₹799

/100

Business quality — Solid

Growth 50Profitability 84Efficiency 95Valuation 93

Plain English

Our view

Debt-free and consistently profitable
Virtually debt-free balance sheet

Strengths

Virtually debt-free balance sheet
Capital is working hard (ROCE 27%)

How we got there

Fair value methods

Residual income

19% ROE fading to 12% over ~10 yrs, on ₹446 book

₹596

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹799

Analyst target

No analyst coverage

—

Blended fair value₹640

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Capital is working hard (ROCE 27%)

Bear case

No notable red flags from the current metrics.

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

15.0Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

18.7%Strong

Above 15% is considered healthy for Indian equities

ROCE

27.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.01Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹485 Cr

P/B

2.44

EPS

₹72.64

Div Yield

1.65%

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

Attractive

P/E 15.0×

Growth

Steady

+7% rev CAGR

Profitability

Excellent

18.7% ROE

Financial health

Rock solid

D/E 0.01

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover₹3.86L Cr

Trades34

VWAP₹1095.54

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+7.2%

+9.1%

10Y

+6.0%

Profit

+10.7%

+16.2%

10Y

+11.9%

EPS

+4.4%

+12.1%

10Y

+10.6%

Profile

Pros

Company has reduced debt.
Company is almost debt free.
Company has been maintaining a healthy dividend payout of 25.7%

Watch-outs

Cons

The company has delivered a poor sales growth of 9.08% over past five years.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

47%

Promoter

Promoters

46.6%-0.02

Public

41.0%+0.02

FII / FPI

0.0%0.00

DII

0.1%0.00

Others

12.2%

Total shareholders

7,103+104 QoQ

Quarterly trend

Ownership over time

Q1 FY27

Promoter46.62%

DII0.12%

Public41.05%

Others12.21%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1985, Jenburkt Pharmaceuticals Ltd manufactures and markets branded Pharmaceuticals and health care products[1]